Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: the place of rituximab and plasma exchange?

Pauline MorelAlexandre KarrasRaphaël PorcherXavier BelenfantVincent AudardCédric RafatGuillaume HanounaSéverine BeaudreuilCédric VilainAurélie HummelBenjamin TerrierEvangeline PilleboutMatthieu GrohRomain JouenneRobin DhoteOlivier FainMatthieu PonsoyeNicolas NoelNicolas LimalXavier PuechalClaire Le JeunneLoïc GuillevinLuc MouthonAlexis Régent

Published in: Rheumatology (Oxford, England) (2022)

We could not find any difference between RTX and CYC as induction therapy for patients with severe AAV-related glomerulonephritis. In patients receiving CYC induction regimen, the addition of PE conferred short-term benefits with higher dialysis-free rate at M12.

Keyphrases

early onset
chronic kidney disease
diffuse large b cell lymphoma
end stage renal disease
hodgkin lymphoma
gene therapy
chronic lymphocytic leukemia